After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platform

After announcing the “tough but necessary” decision to lay off some employees last year, Frontier Medicines is looking to the future by advancing more cancer drugs into the clinic while continuing to find partners to leverage its AI proteomic platform.